LEXINGTON, Mass., Sept. 21, 2017 /PRNewswire/ -- Pulmatrix,
Inc. (NASDAQ: PULM) will present at the Cantor
Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2017 at 2:15 PM EDT in the Intercontinental New York
Barclay Hotel in New York City. As
part of the presentation, Robert W. Clarke, Ph.D., Chief Executive
Officer for Pulmatrix, will provide an update on the Company's
business and its pipeline of inhaled therapeutics.
The presentation will provide updates on the lead pipeline
programs and highlight Pulmatrix's recent in-licensing of narrow
spectrum kinase inhibitors (NSKI) from RespiVert Ltd., a wholly
owned subsidiary of Janssen Biotech, Inc.
About
Pulmatrix
Pulmatrix is a clinical stage biopharmaceutical company developing
innovative inhaled therapies to address serious pulmonary disease
using its patented iSPERSE™ technology. The Company's proprietary
product pipeline is focused on advancing treatments for rare
diseases, including PUR1900, an inhaled anti-fungal for patients
with severe asthma and cystic fibrosis (CF), and PUR1800, a narrow
spectrum kinase inhibitor for patients with COPD. In addition,
Pulmatrix is pursuing opportunities in major pulmonary diseases
through collaborations, including PUR0200, a branded generic in
clinical development for COPD. Pulmatrix's product candidates
are based on iSPERSE™, its proprietary dry powder delivery
platform, which seeks to improve therapeutic delivery to the lungs
by maximizing local concentrations and reducing systemic side
effects to improve patient outcomes.
FORWARD-LOOKING STATEMENTS
Certain statements in this
press release that are forward-looking and not statements of
historical fact are forward-looking statements within the meaning
of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. The Company cautions that such statements
involve risks and uncertainties that may materially affect the
Company's results of operations. Such forward-looking statements
are based on the beliefs of management as well as assumptions made
by and information currently available to management. Actual
results could differ materially from those contemplated by the
forward-looking statements as a result of certain factors,
including but not limited to the ability to establish that
potential products are efficacious or safe in preclinical or
clinical trials; the ability to establish or maintain
collaborations on the development of therapeutic candidates; the
ability to obtain appropriate or necessary governmental approvals
to market potential products; the ability to obtain future funding
for developmental products and working capital and to obtain such
funding on commercially reasonable terms; the Company's ability to
manufacture product candidates on a commercial scale or in
collaborations with third parties; changes in the size and nature
of competitors; the ability to retain key executives and
scientists; and the ability to secure and enforce legal rights
related to the Company's products, including patent protection. A
discussion of these and other factors, including risks and
uncertainties with respect to the Company, is set forth in the
Company's filings with the Securities and Exchange Commission,
including its annual report on Form 10-K filed by the Company with
the Securities and Exchange Commission on March 10, 2017, as may be supplemented or amended
by the Company's Quarterly Reports on Form 10-Q. The Company
disclaims any intention or obligation to revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by law.
Investor
Contact
|
|
Robert Clarke,
CEO
|
William Duke,
CFO
|
(781)
357-2333
|
(781)
357-2333
|
rclarke@pulmatrix.com
|
wduke@pulmatrix.com
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/pulmatrix-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-on-september-27-2017-300522563.html
SOURCE Pulmatrix, Inc.